+

WO1996025507A3 - Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines - Google Patents

Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines Download PDF

Info

Publication number
WO1996025507A3
WO1996025507A3 PCT/US1996/002336 US9602336W WO9625507A3 WO 1996025507 A3 WO1996025507 A3 WO 1996025507A3 US 9602336 W US9602336 W US 9602336W WO 9625507 A3 WO9625507 A3 WO 9625507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
cancer
adenoviral vectors
wild
Prior art date
Application number
PCT/US1996/002336
Other languages
English (en)
Other versions
WO1996025507A9 (fr
WO1996025507A2 (fr
Inventor
Prem K Seth
Kenneth Cowan
Original Assignee
Us Health
Prem K Seth
Kenneth Cowan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Prem K Seth, Kenneth Cowan filed Critical Us Health
Priority to AU52974/96A priority Critical patent/AU5297496A/en
Publication of WO1996025507A2 publication Critical patent/WO1996025507A2/fr
Publication of WO1996025507A3 publication Critical patent/WO1996025507A3/fr
Publication of WO1996025507A9 publication Critical patent/WO1996025507A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux procédés pour construire des vecteurs adénoviraux recombinés, capables d'exprimer des ADNc humains, tels que p53 de type sauvage, WAF1/Cip1/p21, p27/kip1, désaminase de cytosine de E. coli, p16 de type sauvage, TAM 67 (un mutant négatif dominant jun/fos) et B7-1 et B7-2. Cette invention se rapporte en outre à des procédés pour inhiber la prolifération de cellules, pour inhiber le cycle de cellules proliférantes, et à des procédés pour éradiquer des cellules, en particulier des cellules cancéreuses et malades, en infectant ces cellules avec un vecteur d'adénovirus recombiné capable d'exprimer des ADNc humains. Des compositions et des procédés objets de cette invention peuvent servir à traiter des sujets souffrant d'une tumeur, dont des cellules sont privées de l'allèle p53 de type sauvage et/ou possèdent un gène p53 ayant subi une mutation. Cette invention se rapporte en outre à un procédé d'utilisation de vecteurs adénoviraux dans le traitement de cellules cancéreuses, telles que des cellules du cancer des poumons et des cellules du cancer du sein. Cette invention se rapporte en outre à des procédés d'utilisation de vecteurs adénoviraux dans la thérapie génique du cancer, comme mécanisme pour purger les cellules de la moelle osseuse des cellules tumorales contaminantes, pour éradiquer les cellules cancéreuses et pour empêcher le développement de cellules cancéreuses et de tumeurs.
PCT/US1996/002336 1995-02-17 1996-02-16 Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines WO1996025507A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52974/96A AU5297496A (en) 1995-02-17 1996-02-16 Methods of preparation and use of recombinant adenoviral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39060495A 1995-02-17 1995-02-17
US08/390,604 1995-02-17

Publications (3)

Publication Number Publication Date
WO1996025507A2 WO1996025507A2 (fr) 1996-08-22
WO1996025507A3 true WO1996025507A3 (fr) 1996-11-07
WO1996025507A9 WO1996025507A9 (fr) 1996-12-27

Family

ID=23543161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002336 WO1996025507A2 (fr) 1995-02-17 1996-02-16 Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines

Country Status (2)

Country Link
AU (1) AU5297496A (fr)
WO (1) WO1996025507A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
NZ313828A (en) * 1995-07-17 1999-02-25 Univ Texas Expression constructs containing the encoding region of p16 and its regulatory elements and their application in cancer therapy e.g. a replication deficient adenviral vector containing p16
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
FR2755148B1 (fr) * 1996-10-31 1999-01-29 Calvo Fabien Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement
US6177272B1 (en) * 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999025195A1 (fr) * 1997-11-18 1999-05-27 Canji, Inc. Purge de produits de cellules souches
AU762493B2 (en) * 1998-03-11 2003-06-26 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
DE19830907A1 (de) * 1998-07-10 2000-03-16 Max Delbrueck Centrum Verfahren zur Optimierung der Produktion von Adenovirus-Vektoren
DE19860602A1 (de) * 1998-12-29 2000-07-06 Max Delbrueck Centrum Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
EP1279739A1 (fr) * 2001-07-26 2003-01-29 Vrije Universiteit Brussel Vecteurs recombinants derivés des virus adéno-associés exprimant TAM67 pour la thérapie génique
US20060247190A1 (en) 2002-10-21 2006-11-02 Kathleen Beach Compositions and methods for treating human papillomavirus mediated disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024297A1 (fr) * 1993-04-22 1994-10-27 Rhone-Poulenc Rorer S.A. Adenovirus recombinants defectifs pour la therapie genique des tumeurs
WO1995010623A1 (fr) * 1993-10-13 1995-04-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Transfert selectif adenoviral de genes vers les cellules neointimales vasculaires
WO1995012660A2 (fr) * 1993-10-29 1995-05-11 Board Of Regents, The University Of Texas System Procedes et compositions relatifs a l'adenovirus p53 recombine
WO1995013375A1 (fr) * 1993-11-10 1995-05-18 The Johns Hopkins University Waf1 anti-tumoral
WO1995018824A1 (fr) * 1994-01-07 1995-07-13 Sloan-Kettering Institute For Cancer Research PROTEINE p27 ISOLEE ET MOLECULES D'ACIDE NUCLEIQUE CODANT CETTE PROTEINE
WO1996015245A1 (fr) * 1994-11-11 1996-05-23 Arch Development Corporation Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024297A1 (fr) * 1993-04-22 1994-10-27 Rhone-Poulenc Rorer S.A. Adenovirus recombinants defectifs pour la therapie genique des tumeurs
WO1995010623A1 (fr) * 1993-10-13 1995-04-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Transfert selectif adenoviral de genes vers les cellules neointimales vasculaires
WO1995012660A2 (fr) * 1993-10-29 1995-05-11 Board Of Regents, The University Of Texas System Procedes et compositions relatifs a l'adenovirus p53 recombine
WO1995013375A1 (fr) * 1993-11-10 1995-05-18 The Johns Hopkins University Waf1 anti-tumoral
WO1995018824A1 (fr) * 1994-01-07 1995-07-13 Sloan-Kettering Institute For Cancer Research PROTEINE p27 ISOLEE ET MOLECULES D'ACIDE NUCLEIQUE CODANT CETTE PROTEINE
WO1996015245A1 (fr) * 1994-11-11 1996-05-23 Arch Development Corporation Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. KAYATOSE ET AL.: "Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 215, no. 2, 1995, pages 446 - 451, XP002012685 *
D. KAYATOSE ET AL.: "Cytoroxic effects of adenovirus-mediated wild-type p53 peotein expression in normal and tumor mammary epithelial cells", CLINICAL CANCER RESEARCH, vol. 1, 1995, pages 889 - 897, XP002012686 *
F. GRAHAM: "Adenoviruses as expression vectors and recombinant vaccines", TRENDS IN BIOTECHNOLOGY, vol. 8, no. 4, 1990, pages 85 - 87, XP002012682 *
W. ZHANG ET AL.: "Anti-oncogene and tumour suppressor gene therapy - examples from a lung cancer model", IN VIVO, vol. 8, 1994, pages 755 - 770, XP002012683 *
X. JIN ET AL: "Cell cycle arrest and inhibition of tumour cell proliferation by the p16ink4 gene mediated by an adenovirus vector", CANCER RESEARCH, vol. 55, 1995, pages 3250 - 3253, XP002012684 *

Also Published As

Publication number Publication date
AU5297496A (en) 1996-09-04
WO1996025507A2 (fr) 1996-08-22

Similar Documents

Publication Publication Date Title
WO1996025507A3 (fr) Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines
Crouzet et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes
GR3022909T3 (en) Retroviral vectors useful for gene therapy
Zeng et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation
EP1923467A3 (fr) Vecteurs d'adénovirus pour thérapie génétique
IL108446A (en) Computer-based methods and articles of manufacture for preparing g-csf analogs
WO1995006743A3 (fr) Procedes et compositions de production a grande echelle de virus adeno-associe recombine
CA2286873A1 (fr) Hybrides de cellules dendritiques
Mhashilkar et al. Gene therapy: therapeutic approaches and implications
CA2148934A1 (fr) Particules vectorielles ciblables
WO2000073478A3 (fr) Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
AU3002497A (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
AU5318496A (en) Adenovirus vectors for gene therapy
WO1999058656A3 (fr) Liberation prolongee d'adn depuis des matrices structurales
Dorudi et al. Gene transfer therapy in cancer
WO1995034669A3 (fr) Vecteurs retroviraux de therapie genique et procedes therapeutiques correspondants
Rancourt et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary.
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
AU4743596A (en) Methods of preparing bone marrow stromal cells for use in gene therapy
Nagano et al. Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy
WO1997015668A3 (fr) Procedes et compositions comprenant glut-2 et des chimeres de glut-2
Higuchi et al. Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines
EP1593742A3 (fr) Vecteurs adénoviraux recombinants pour l'infection spécifique de céllules qui expriment des proteines fibreuses chimériques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KG KZ MD RU TJ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/41-41/41, DRAWINGS, REPLACED BY NEW PAGES 1/42-42/42

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载